Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.

Read the original research

Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.

Diabetes, obesity & metabolism

Citation

Sørensen, Kathrine Kold; Yazdanfard, Puriya Daniel Würtz; Zareini, Bochra; Wood-Kurland, Hannah Karin; Pedersen-Bjergaard, Ulrik; Andersen, Mikkel Porsborg; Michelsen, Jens; Imberg, Henrik; Lind, Marcus; Hallström, Sara; Lanzinger, Stefanie; Munch, Anders; Ohlendorff, Johan Sebastian; Gerds, Thomas Alexander; Torp-Pedersen, Christian. (2026). Sustained glucagon-like peptide-1 receptor agonist treatment improves glycemic control and reduces all-cause mortality compared to dipeptidyl peptidase-4 inhibitors: A real-world target trial emulation in type 2 diabetes.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70581